Entresto Gets Boost in Updated HF Guidelines

–Valsartan/sacubitril earns Class I recommendation Cardiology groups in the U.S. and Europe have updated their heart failure guidelines to include much-awaited recommendations for Entresto (the combination of valsartan and sacubitril manufactured by Novartis). The new guidelines offer broad support for the new drug. Since its approval last summer Entresto has struggled to gain a foothold...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: Heart Failure People, Places & Events Policy & Ethics Entresto guidelines LCZ Source Type: blogs